Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
复制标题
DOI:
10.1007/s10096-022-04526-0
复制
发表时间:
2023-01
影响因子:
4.5
通讯作者:
Nordmann, Patrice
中科院分区:
文献类型:
--
作者:
Sadek, Mustafa;Le Guern, Remi;Kipnis, Eric;Gosset, Philippe;Poirel, Laurent;Dessein, Rodrigue;Nordmann, Patrice
We report in vivo development of cefiderocol (FDC) resistance among four sequential Pseudomonas aeruginosa clinical isolates ST244 recovered from a single patient, without exposure to FDC, which raises concern about the effectiveness of this novel drug. The first recovered P. aeruginosa isolate (P-01) was susceptible to FDC (2 μg/mL), albeit this MIC value was higher than that of a wild-type P. aeruginosa (0.12–0.25 μg/ml). The subsequent isolated strains (P-02, P-03, P-04) displayed increasing levels of FDC MICs (8, 16, and 64 μg/ml, respectively). Those isolates also showed variable and gradual increasing levels of resistance to most β-lactams tested in this study. Surprisingly, no acquired β-lactamase was identified in any of those isolates. Whole-genome sequence analysis suggested that this resistance was driven by multifactorial mechanisms including mutational changes in iron transporter proteins associated with FDC uptake, ampC gene overproduction, and mexAB-oprM overexpression. These findings highlight that a susceptibility testing to FDC must be performed prior to any prescription.
登录
查看更多内容
影响因子:
2.6
作者:
Nordmann, Patrice;Shields, Ryan K.;Doi, Yohei;Takemura, Miki;Echols, Roger;Matsunaga, Yuko;Yamano, Yoshinori
通讯作者:
Yamano, Yoshinori
影响因子:
4.9
作者:
Bagge, N;Ciofu, O;Hoiby, N
通讯作者:
Hoiby, N
DOI:
10.1016/j.diagmicrobio.2019.03.003
发表时间:
2019-08-01
影响因子:
2.9
作者:
Hackel, Meredith A.;Tsuji, Masakatsu;Sahm, Daniel F.
通讯作者:
Sahm, Daniel F.
影响因子:
4.6
作者:
Kohira, Naoki;Hackel, Meredith A.;Yamano, Yoshinori
通讯作者:
Yamano, Yoshinori
影响因子:
4.9
作者:
Malik, Saquib;Kaminski, Monica;Quale, John
通讯作者:
Quale, John